ACOG

The Inner Circle acknowledges Jaleen D. Sims, MD, MPH, FACOG as a Pinnacle Lifetime Member

Retrieved on: 
Friday, March 22, 2024
Well, Health, Organization, Birth, Gynaecology, Motivation, Public health, HOPE, Mentorship, Trust, FACOG, Patient, Knowledge, MSMA, University, MMSA, Woman, Wichita State University, American College, MPH, ACOG, Multimedia, Family, Physician, Inner circle, Medicine, Nursing

FLOWOOD, Miss., March 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jaleen D. Sims, MD, MPH, FACOG is acknowledged as a Pinnacle Lifetime Member for her contributions as a Leading Obstetrics and Gynecology Specialist.

Key Points: 
  • FLOWOOD, Miss., March 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jaleen D. Sims, MD, MPH, FACOG is acknowledged as a Pinnacle Lifetime Member for her contributions as a Leading Obstetrics and Gynecology Specialist.
  • Dr. Jaleen D. Sims, MD, MPH, FACOG, practicing board certified OB/GYN at Jackson-Hinds Comprehensive Health Center in Jackson, MS, is a leading figure in women's healthcare.
  • She is making waves in Mississippi with her expertise in normal and high-risk pregnancies, minimally invasive gynecological procedures, teen gynecology, contraception, and preventative cancer screenings.
  • Her dedication to advancing women's healthcare has earned her the trust and admiration of both patients and peers.

BayCare's St. Joseph's Women's Hospital Achieves Level IV Maternal Care Certification from The Joint Commission

Retrieved on: 
Thursday, March 21, 2024
Consensus, Mother, RN, Disease, Certification, Culture, Cone Health Women's Hospital, Level, Central Florida, Woman, Joint Commission, MLC, Mental, Partnership, Education, Verification, DNP, Patient, Mental health, Mortality, Anesthesiology, University, MBA, American College, OCC, Hospital, ACOG, Health, Nursing

TAMPA, Fla., March 21, 2024 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, today announced that St. Joseph's Women's Hospital has attained the highest level of certification in Maternal Care by The Joint Commission, the nation's oldest health care accrediting organization.

Key Points: 
  • TAMPA, Fla., March 21, 2024 /PRNewswire/ -- BayCare, the leading health care system in West Central Florida, today announced that St. Joseph's Women's Hospital has attained the highest level of certification in Maternal Care by The Joint Commission, the nation's oldest health care accrediting organization.
  • As a Level IV maternal care verified facility, St. Joseph's Women's Hospital is recognized for its commitment to providing exceptional maternal healthcare services.
  • "The Joint Commission commends St. Joseph's Women's Hospital for being named a Level IV maternal care verified facility and for its efforts to standardize maternal care and reduce maternal morbidity and mortality," says Ken Grubbs, DNP, MBA, RN, executive vice president of Accreditation and Certification Operations and chief nursing officer, The Joint Commission.
  • "The Maternal Levels of Care Verification program will help St. Joseph's Women's Hospital strengthen regionalized care for mothers and babies in its community."

Cepheid Receives FDA Clearance for Xpert® Xpress GBS

Retrieved on: 
Monday, March 11, 2024
PCR, Obstetrics, Streptococcus, Rheumatic fever, EVP, INT, Risk, Cepheid variable, Antibiotic prophylaxis, Antimicrobial stewardship, Fungal infection, Genome, Woman, American College, GBS, Negative, ACOG, Infant, Food, Sintering

SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS). This next-generation test incorporates new dual targets in highly-conserved regions of the GBS genome to improve sensitivity and bacterial strain coverage. The test is designed for use on Cepheid's GeneXpert® systems.

Key Points: 
  • SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS).
  • Xpert Xpress GBS allows for the use of intrapartum direct PCR testing for women with unknown or unavailable antepartum GBS status.
  • With the capability of returning positive results as early as 30 minutes,2 Xpert Xpress GBS can provide real-time GBS status and inform decisions about empiric antibiotic prophylaxis if appropriate, to prevent GBS transmission during birth.
  • With Xpert Xpress GBS, Cepheid continues to provide fast, accurate, and reliable PCR solutions to facilitate evidence-based treatment and improved clinical care.

Igentify Launches New NIPT and Pharmacogenomics Offerings

Retrieved on: 
Tuesday, March 5, 2024
Technology, Science, Family, Genetics, Consumer, Clinical Trials, Biotechnology, Health, Health Technology, Apps, Applications, Research, Software, Other Health, Internet, Parenting, Pharmaceutical, Baby, Maternity, ACOG, NIPT, ECS, Workflow

Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.

Key Points: 
  • Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.
  • This new roll-out comes in addition to their Expanded Carrier Screening (ECS) offering.
  • The NIPT workflow includes a patient web-app that facilitates all aspects of patient intake, including an ACOG-compliant consenting process using Igentify’s proprietary video technology to create highly personalized educational videos for each patient.
  • “We are thrilled to expand the accessibility of our platform with programs focused on non-invasive prenatal testing and pharmacogenomics,” said Elliott Greenspan, Chief Innovation Officer and Co-founder of Igentify.

Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease

Retrieved on: 
Thursday, February 22, 2024
Research, Patent Law, Neurology, FDA, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Therapy, ACOG, Clinical trial, File, Patent, ACI, Patient

The present composition-of-matter patent application is filed for approval with the USPTO and may be extended to pursue protection throughout the world and, if approved, will secure composition-of-matter protection for an oral formulation of ALPHA-1062.

Key Points: 
  • The present composition-of-matter patent application is filed for approval with the USPTO and may be extended to pursue protection throughout the world and, if approved, will secure composition-of-matter protection for an oral formulation of ALPHA-1062.
  • The filing was based on novel and unexpected findings in the clinical trial work the company completed and further demonstrates the uniqueness of ALPHA-1062.
  • If approved, the patent will provide protection for ALPHA-1062 into 2044, adding to other patent protection that currently protect ALPHA-1062 through 2042.
  • “Filing this patent application is an important component of our strategy to ensure broad protection for ALPHA-1062, a next generation treatment option for patients suffering from mild-to-moderate Alzheimer’s Disease.

Alpha Cognition Provides Business Update

Retrieved on: 
Monday, February 12, 2024
Mental Health, FDA, Neurology, Public Relations, Investor Relations, Communications, Biotechnology, Health, Pharmaceutical, General Health, Therapy, Food and Drug Administration, Nursing care plan, Physician, Food, Overalls, LTC, Patient, ACOG, Insomnia, Tablet, NDA, Pharmaceutical industry

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update.

Key Points: 
  • Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercialization strategy, and a pipeline update.
  • ALPHA-1062 has a Prescription Drug User Fee Act (“PDUFA”) date (drug approval date) in the U.S. for July 27, 2024.
  • Alpha Cognition’s commercialization strategy includes our initial commercial launch in LTC, followed by expansion to the Neurology segment once payer reimbursement has been established.
  • For other Alpha Cognition programs the Company will explore out-licensing our progranulin and Granulin Epithelin Motifs (“GEM”) programs.

Boston IVF Welcomes Reproductive Endocrinologist Jamil Mroueh, MD to its Rochester Fertility Center Team

Retrieved on: 
Thursday, February 8, 2024
SUNY Downstate Medical Center, American College, American University, Infertility, Greater, REI, MD, Patient, Fertility, IUI, PCOS, ACOG, Acquisition, Education, State university system, Health, IVF, Birth control

 ROCHESTER, Mass., Feb. 8, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce that reproductive endocrinologist, Jamil Mroueh, MD has joined its fertility center in Rochester, NY.

Key Points: 
  • Dr. Jamil Mroueh's Arrival Bolsters Access to Prompt Reproductive Care at Boston IVF and its Rochester, NY Fertility Center.
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.
  • Boston IVF's Rochester fertility center is located at 1561 Long Pond Rd Suite 410, Rochester, NY 14626 .
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.

Axena Health Commends New Study Showing the Leva System’s Long-term Treatment Efficacy for Female Urinary Incontinence

Retrieved on: 
Tuesday, January 23, 2024
Women, Seniors, Physical Therapy, Health, FDA, Medical Devices, Health Technology, Consumer, Woman, Patient, Reproductive biology, Associate, MD, The Green Journal, Overactive bladder, Female, RCT, Harvard Medical School, Manager, FACS, PFMT, Urinary incontinence, University, Medicine, Quality of life, Risk, Incontinence, Food, Journal, FACOG, Storey, UI, Hospital, ACOG, Massachusetts General Hospital, American College, Birth control

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).

Key Points: 
  • Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).
  • “Two years of data showing that UI symptom relief endures following eight weeks of guided-PFMT offers compelling evidence that women can access first-line, conservative treatment successfully.
  • “This newest published study offers powerful evidence that women can access first-line treatment successfully, and that this treatment has a lasting effect.
  • “Pelvic floor muscle training is globally recommended first-line treatment for urinary incontinence,” said Eileen Maus, CEO of Axena Health.

Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment

Retrieved on: 
Friday, January 19, 2024
Software, Networks, Internet, Artificial Intelligence, Data Management, Technology, Apps, Applications, Mobile, Wireless, OTCQB, ACOG, Research, News, Person, Security (finance)

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company.

Key Points: 
  • Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company.
  • Pursuant to the final closing, the Company issued 16,965,762 units of the Company at a price of US$0.22 per unit for gross proceeds of US$3,732,467.
  • The gross proceeds of the offering received to date are US$8.45 million, which includes shares of the fully subscribed 30% overallotment.
  • The Company expects to use the net proceeds from the private placement for research and development, general and administrative matters, and working capital.

Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids

Retrieved on: 
Tuesday, January 2, 2024
Category 1, Constipation, Commercial, Hysterectomy, Woman, Uterine fibroid, Language, Place of birth, Literature, ACOG, Sonata, American Medical Association, Medicare, Obstetrics, Fibroid, American College, Uterus, Current Procedural Terminology, CPT, Patient, Pressure

The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.

Key Points: 
  • The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.
  • Commenting on the new CPT code, Skip Baldino, President and Chief Executive Officer of Gynesonics said, “We are very pleased that the AMA has established a new Category I code that applies to our Sonata® Procedure for the treatment of uterine fibroids.
  • The code is a critical milestone for the broader adoption of the technology to treat uterine fibroids in the United States.
  • Fibroids are treated from inside the uterus, so the Sonata Procedure requires no incisions, no tissue is surgically removed, and the uterus is preserved.